Affinage

PSMB5

Proteasome subunit beta type-5 · UniProt P28074

Length
263 aa
Mass
28.5 kDa
Annotated
2026-06-10
39 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PSMB5 encodes the chymotrypsin-like catalytic subunit of the 20S proteasome core, and its activity sets the rate of proteasomal protein degradation (PMID:18565852, PMID:20555361). Under IFN-γ stimulation the constitutive PSMB5 subunit is replaced by the inducible LMP7 (PSMB8) subunit during immunoproteasome formation (PMID:9382924). PSMB5 is the direct molecular target of bortezomib, which binds within its active-site pocket; point mutations at Ala49/Ala50 and gene amplification/overexpression confer graded drug resistance by reducing inhibitor binding and preventing the accumulation of polyubiquitinated proteins and the resulting ER stress and apoptosis (PMID:18565852, PMID:19426847, PMID:20555361), and these mutations cross-resist second-generation inhibitors carfilzomib, ONX0912, and ONX0914 (PMID:22235146). PSMB5 expression is controlled by a convergent set of regulators: the Nrf2-ARE pathway (PMID:16723119, PMID:30762899), STAT3 acting at the PSMB5 promoter (PMID:24627483), TGF-β/Smad3 via a Smad-binding element (PMID:28807746), Gα12/13 signaling (PMID:20478922), and the transcription factor THAP1, which binds the PSMB5 locus to drive basal proteasome expression — THAP1 loss collapses proteasome assembly and activity in a manner rescued by exogenous PSMB5 (PMID:39929834, PMID:39952963). Post-transcriptionally, PSMB5 is repressed by miR-142-3p and miR-127-3p targeting its 3'UTR (PMID:31562641, PMID:32866906) and translationally enhanced by METTL16 through suppression of eIF2α phosphorylation (PMID:41826420). Functionally, PSMB5-dependent degradation controls specific substrates including Drp1, linking proteasome activity to mitochondrial fission/fusion (PMID:30762899, PMID:34394840), and Hobit, regulating CD4+ tissue-resident memory T cell differentiation (PMID:39037181); PSMB5 activity also sustains proteostasis in cellular senescence and oxidative-stress resistance (PMID:24393841).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1997 Medium

    Established PSMB5 as the constitutive catalytic subunit whose place in the 20S core is exchangeable, defining the substitution by inducible LMP7 that switches proteasome specificity upon immune stimulation.

    Evidence Gene structure analysis, interspecific backcross mapping, and FISH in mouse

    PMID:9382924

    Open questions at the time
    • Subunit replacement was inferred rather than directly reconstituted
    • No catalytic mechanism or substrate spectrum addressed
  2. 2006 High

    Identified the first upstream transcriptional control of PSMB5, showing inducer-driven expression runs through the Nrf2-ARE pathway rather than AhR/XRE signaling.

    Evidence Promoter deletion/mutation luciferase reporters, Nrf2-null cells, and proteasome activity assays

    PMID:16723119

    Open questions at the time
    • Does not link Nrf2-driven PSMB5 levels to specific degradation substrates
    • Other constitutive regulators not surveyed
  3. 2008 High

    Demonstrated that PSMB5 is the direct pharmacological target of bortezomib and that an active-site Ala49 mutation suffices for resistance, settling the drug's mechanism of action.

    Evidence Stepwise drug selection, cDNA sequencing, siRNA rescue, and chymotrypsin-like activity assays; FISH/RT-PCR for amplification

    PMID:18562081 PMID:18565852

    Open questions at the time
    • Structural basis of altered drug binding not resolved at atomic level
    • Did not establish whether amplification arises clinically
  4. 2010 High

    Showed mutant PSMB5 is sufficient to confer resistance by blocking polyubiquitinated protein accumulation and downstream ER stress/apoptosis, and that Gα12/13 signaling tunes PSMB5 levels and bortezomib sensitivity.

    Evidence Mutant vs. wild-type PSMB5 transfection with CHOP/caspase Western blots; Gα12/13 minigene inhibition and constitutively active mutants

    PMID:20478922 PMID:20555361

    Open questions at the time
    • The downstream effectors connecting Gα12/13 to the PSMB5 promoter were not mapped
    • ER stress link is correlative with activity, not substrate-specific
  5. 2012 Medium

    Defined that PSMB5 active-site mutations produce graded, mutation-specific cross-resistance to second-generation proteasome inhibitors, generalizing the resistance mechanism beyond bortezomib.

    Evidence Cytotoxicity and chymotrypsin-like activity assays in genetically defined PSMB5 mutant lines across an inhibitor panel

    PMID:22235146

    Open questions at the time
    • P-glycoprotein contribution not separated from PSMB5 mutation effects
    • Single-lab cell-line panel
  6. 2014 High

    Expanded the transcriptional control map by establishing STAT3 as a direct PSMB5 promoter regulator and linked PSMB5 levels to proteostatic maintenance against senescence and oxidative stress.

    Evidence STAT3 gain/loss-of-function with promoter reporters; lentiviral PSMB5 overexpression/knockdown in hBMSCs with proliferation, differentiation, and H2O2 survival assays

    PMID:24393841 PMID:24627483

    Open questions at the time
    • Cyclin D1/CDK4 link to proliferation remains correlative
    • Senescence phenotype mechanism not tied to specific substrates
  7. 2017 Medium

    Added TGF-β/Smad3 as a direct PSMB5 promoter input via a Smad-binding element, connecting lipid-mediator (20-HETE) signaling to proteasome subunit expression.

    Evidence Luciferase reporters, EMSA showing direct Smad3 binding, and TGF-β receptor inhibitor rescue in transgenic mice

    PMID:28807746

    Open questions at the time
    • Physiological consequence of altered PSMB5 in this context not defined
    • Single-lab
  8. 2019 Medium

    Identified post-transcriptional repression of PSMB5 by miR-127-3p and placed PSMB5 downstream of Nrf2 in driving proteasomal degradation of Drp1, linking it to mitochondrial fission control.

    Evidence miR-127-3p 3'UTR reporter and CTCF ChIP; Nrf2 siRNA epistasis with epoxomicin rescue and mitochondrial morphology readouts

    PMID:30762899 PMID:31562641

    Open questions at the time
    • Direct PSMB5-mediated cleavage of Drp1 not shown biochemically
    • Single-lab for each axis
  9. 2020 Medium

    Established miR-142-3p as a second direct PSMB5-repressing microRNA controlled by p300, and that lowering PSMB5 reduces 20S chymotrypsin-like activity, validated in vivo.

    Evidence miR-142-3p 3'UTR reporter, p300 gain/loss-of-function, proteasome activity assays, and xenografts

    PMID:32866906

    Open questions at the time
    • Relative contribution of multiple miRNAs to physiological PSMB5 not weighed
    • Single-lab
  10. 2021 Medium

    Implicated PSMB5 proteasome activity in additional signaling outputs — Nmnat2/SIRT6 activation and CXCR4-driven Drp1 proteolysis governing mitochondrial fusion.

    Evidence Pharmacological PSMB5 inhibition with downstream Nmnat2/SIRT6 readouts; receptor/PSMB5 inhibitors and NRF2 siRNA with mitochondrial imaging

    PMID:33315278 PMID:34394840

    Open questions at the time
    • Effects rely on pharmacological inhibition that affects whole 20S activity, not PSMB5 selectively
    • Direct substrate engagement not shown
  11. 2022 High

    Revealed a non-mutational resistance mechanism in which ISG20L2 directly binds bortezomib and competes for the drug, sparing PSMB5 activity; also showed PSMB5 knockdown suppresses CGG-repeat neurodegeneration.

    Evidence Biotinylated bortezomib pull-down and SPR for ISG20L2 binding with in vivo validation; Drosophila/N2A FXTAS models with RAN translation assays

    PMID:35617426 PMID:36040812

    Open questions at the time
    • How ISG20L2 expression is regulated in resistant patients unaddressed
    • FXTAS protective mechanism via PSMB5 not mechanistically resolved
  12. 2024 Medium

    Connected mitochondrial metabolism to PSMB5 expression and immune cell fate: succinylation of BRD2 impairs PSMB5 transcription, raising Hobit and driving CD4+ Trm differentiation.

    Evidence ChIP-qPCR for BRD2 at PSMB5, succinyl-CoA manipulation, and humanized NSG chimera Trm assays

    PMID:39037181

    Open questions at the time
    • Direct PSMB5-mediated degradation of Hobit not biochemically demonstrated
    • Single-lab
  13. 2025 High

    Identified THAP1 as a direct transcriptional driver of basal PSMB5 expression and proteasome assembly, distinct from Nrf1 compensation, with METTL16 providing parallel translational enhancement.

    Evidence DepMap coessentiality, THAP1 ChIP at PSMB5, PSMB5 rescue of THAP1-loss toxicity, deep mutational scan; METTL16 gain/loss with eIF2α/polysome assays

    PMID:39929834 PMID:39952963 PMID:41826420

    Open questions at the time
    • Relationship between THAP1-driven PSMB5 control and dystonia phenotypes not addressed
    • METTL16's m6A-independent mechanism mechanistically incomplete

Open questions

Synthesis pass · forward-looking unresolved questions
  • Whether neuronal PSMB5-dependent proteasome activity is causally required for cognitive maintenance during aging remains to be established in peer-reviewed work.
  • Preprint, single lab, limited mechanistic detail
  • No identified neuronal substrate linking PSMB5 to cognition

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 3 GO:0140096 catalytic activity, acting on a protein 2
Pathway
R-HSA-392499 Metabolism of proteins 3 R-HSA-168256 Immune System 1
Partners
ISG20L2PSMB8
Complex memberships
20S proteasomeimmunoproteasome

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 An Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 confers bortezomib resistance; siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity in resistant cells, confirming PSMB5 as the direct target of bortezomib. Stepwise drug selection, cDNA sequencing, siRNA knockdown, chymotrypsin-like proteasome activity assay Blood High 18565852
2008 PSMB5 gene amplification (demonstrated by FISH/ISH) and mRNA overexpression correlate with increased chymotrypsin-like proteasome activity and bortezomib resistance in Jurkat-derived cells. Quantitative RT-PCR, FISH, in situ hybridization, fluorometric chymotrypsin-like activity assay, Western blot Experimental hematology Medium 18562081
2009 Different point mutations in the PSMB5 bortezomib-binding pocket (Ala49Thr, Ala49Val, Ala49Thr+Ala50Val) confer graded levels of bortezomib resistance, with the double mutant conferring the highest resistance and the weakest inhibition of chymotrypsin-like activity by bortezomib. cDNA sequencing, limited dilution cloning, quantitative RT-PCR, fluorometric chymotrypsin-like activity assay, cytotoxicity assay Experimental hematology High 19426847
2010 A G322A point mutation in PSMB5 reduces accumulation of polyubiquitinated proteins and prevents bortezomib-induced ER stress (CHOP upregulation) and apoptosis; transfection of mutant PSMB5 into parental cells recapitulated resistance, confirming the mutation as sufficient for resistance. Sequencing, transfection with wild-type vs. mutant PSMB5, Western blot for ubiquitinated proteins/CHOP/caspase, apoptosis assay Leukemia High 20555361
2006 PSMB5 gene transcription is induced by the bifunctional enzyme inducer 3-methylcholanthrene through the Nrf2-ARE pathway (not the AhR/Arnt-XRE pathway); mutation of proximal AREs in the Psmb5 promoter largely abolished inducibility, and 3-MC failed to induce PSMB5 in nrf2-null cells. Luciferase reporter assay with promoter deletion/mutation constructs, Nrf2 knockout cells, nuclear Nrf2 detection, proteasome activity assay Biochemical and biophysical research communications High 16723119
2012 PSMB5 mutations confer cross-resistance to second-generation proteasome inhibitors carfilzomib, ONX0912, and ONX0914, with the degree of cross-resistance depending on the specific mutation; P-glycoprotein overexpression also reduces chymotrypsin-like proteasome activity inhibition by these agents. Cytotoxicity assays, chymotrypsin-like activity assay in resistant cell lines with defined PSMB5 mutations The Journal of pharmacology and experimental therapeutics Medium 22235146
2014 STAT3 directly regulates PSMB5 promoter activity and protein expression; constitutively active STAT3 induces PSMB5 promoter and protein levels, while STAT3 knockdown or inhibition of STAT3 tyrosine phosphorylation coordinately reduces PSMB5 mRNA and protein and decreases chymotrypsin-like proteasome activity. STAT3 knockdown/inhibition, constitutively active STAT3 overexpression, PSMB5 promoter reporter assay, Western blot, proteasome activity assay The Journal of biological chemistry High 24627483
2014 PSMB5 overexpression restores 20S proteasome activity in senescent human bone marrow stromal cells (hBMSCs), promotes cell proliferation (possibly via upregulation of Cyclin D1/CDK4), and enhances resistance to oxidative stress; PSMB5 knockdown in early-stage cells phenocopies senescence. Lentiviral overexpression/knockdown, proteasome activity assay, BrdU proliferation assay, Western blot, neural differentiation assay, H2O2 stress survival assay Biochemical and biophysical research communications Medium 24393841
2010 Inhibition of Gα12/13 signaling decreases PSMB5 mRNA and protein expression and reduces chymotrypsin-like proteasome activity, thereby enhancing bortezomib cytotoxicity; conversely, constitutively active Gα12QL or Gα13QL increases PSMB5 expression and confers bortezomib resistance. Minigene-mediated G protein inhibition, constitutively active mutant overexpression, real-time PCR, Western blot, proteasome activity assay, cytotoxicity assay Carcinogenesis Medium 20478922
2017 20-HETE regulates PSMB5 expression through the TGF-β/Smad3 signaling pathway: Smad3 directly binds the Smad binding element (SBE) in the PSMB5 promoter, as demonstrated by EMSA and luciferase assays; TGF-β receptor I kinase inhibitor SB431542 reversed 20-HETE-induced changes in PSMB5. Luciferase reporter assay, EMSA, TGF-β receptor inhibitor treatment, Western blot for Smad3 phosphorylation in transgenic mice Prostaglandins & other lipid mediators Medium 28807746
2019 PSMB5 is a direct target of miR-127-3p; overexpression of miR-127-3p reduces PSMB5 protein levels and inhibits prostate cancer cell invasion and migration in vitro. CTCF transcriptionally represses miR-127-3p by binding its promoter, thereby indirectly maintaining PSMB5 expression. miR-127-3p overexpression, luciferase reporter assay (3'UTR targeting), CTCF ChIP/promoter binding assay, invasion/migration assays FEBS letters Medium 31562641
2019 Ilexgenin A (IA) increases PSMB5 expression in an Nrf2-dependent manner; Nrf2 knockdown eliminates IA-induced PSMB5 upregulation and abolishes inhibition of Drp1 expression and mitochondrial fission, placing PSMB5 downstream of Nrf2 in mediating proteasomal degradation of Drp1. Nrf2 siRNA knockdown, Western blot for PSMB5/Drp1, proteasome inhibitor (epoxomicin) rescue experiment, mitochondrial morphology assessment Drug development research Medium 30762899
2020 Curcumin reduces PSMB5 protein levels by elevating miR-142-3p (which directly targets PSMB5 3'UTR), and this reduction is mediated through suppression of histone acetyltransferase p300, which normally inhibits miR-142-3p expression; loss of PSMB5 reduces chymotrypsin-like activity of the 20S proteasome. miR-142-3p overexpression/inhibition, luciferase 3'UTR reporter assay, p300 overexpression, proteasome activity assay, xenograft model, Western blot, qRT-PCR Phytomedicine Medium 32866906
2021 Activation of PSMB5 (chymotrypsin-like proteasome activity) is required for EGCG-induced upregulation of Nmnat2 protein and subsequent SIRT6 activation; PSMB5 inhibition abolished EGCG-induced Nmnat2 protein expression and the anti-hypertrophic effect. PSMB5 pharmacological inhibition, Nmnat2 knockdown, luciferase reporter assay, EMSA for NF-κB, fluorometric SIRT6 activity assay, Western blot Acta physiologica Medium 33315278
2021 rHMGB1 promotes mitochondrial fusion in endothelial cells via CXCR4/PSMB5-mediated Drp1 proteolysis; inhibition of CXCR4 reversed Drp1 downregulation, and inhibition of PSMB5 (but not NRF2 silencing) abolished rHMGB1-induced Drp1 downregulation and mitochondrial fusion, placing PSMB5 downstream of CXCR4 in this pathway. Specific receptor/PSMB5 inhibitors, siRNA for NRF2, Western blot for Drp1/PSMB5, confocal and TEM for mitochondrial morphology Oxidative medicine and cellular longevity Medium 34394840
2022 ISG20L2 directly binds bortezomib and competes with PSMB5 for bortezomib binding, thereby attenuating bortezomib-induced inhibition of PSMB5 proteasome activity and conferring resistance; direct binding of bortezomib to ISG20L2 was confirmed by surface plasmon resonance. Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain/loss-of-function studies, proteasome activity assay, in vivo xenograft JCI insight High 36040812
2022 Knockdown of PSMB5 (Prosbeta5) suppressed CGG repeat-associated neurodegeneration in a Drosophila FXTAS model and in N2A cells via both RAN translation and RNA-mediated toxicity mechanisms. Drosophila genetic screen, PSMB5 knockdown in Drosophila and N2A cells, neurodegeneration assays, RAN translation assay Proceedings of the National Academy of Sciences of the United States of America Medium 35617426
2025 The transcription factor THAP1 directly regulates PSMB5 gene expression; loss of THAP1 reduces PSMB5 levels, disrupts proteasome assembly, reduces proteasome activity, and causes accumulation of ubiquitinated proteins and cell death; exogenous PSMB5 expression rescues toxicity from THAP1 loss. Genome-wide coessentiality analysis (DepMap), THAP1 knockdown/KO, PSMB5 rescue expression, RNA-seq, deep mutational scan of THAP1 variants, proteasome assembly assay, ubiquitinated protein accumulation assay Nature communications High 39929834
2025 THAP1 directly binds the PSMB5 gene and regulates its transcription; THAP1 depletion disrupts proteasome assembly and impairs proteasome activity via reduced PSMB5 expression; this identifies a regulatory mechanism for basal proteasome expression distinct from the Nrf1-mediated compensatory pathway. Genome-wide genetic screen, ChIP for THAP1 at PSMB5 locus, THAP1 knockdown, proteasome assembly assay, ubiquitinated protein accumulation assay Nature communications High 39952963
2024 Mitochondrial succinyl-CoA drives succinylation of BRD2, which impairs BRD2-dependent transcription of PSMB5; reduced PSMB5 expression leads to elevated Hobit protein levels (due to impaired proteasomal degradation) and promotes CD4+ Trm cell differentiation in rheumatoid arthritis. BRD2 identification by chromatin immunoprecipitation-qPCR, succinyl-CoA manipulation in T cells, THAP1 silencing, Trm differentiation assays, humanized NSG chimera model Arthritis & rheumatology Medium 39037181
1997 IFN-γ stimulation causes replacement of the constitutively expressed PSMB5 subunit in the 20S proteasome by the inducible LMP7 (PSMB8) subunit; the mouse Psmb5 gene has a unique three-exon structure spanning ~5 kb, conserved with the human gene, and maps to chromosome 14 band C2–D1. Gene structure analysis, interspecific backcross mapping, fluorescent in situ hybridization (FISH) Immunogenetics Medium 9382924
2025 METTL16 promotes PSMB5 translation in an m6A methyltransferase activity-independent manner by inhibiting the eIF2α-PERK interaction and reducing eIF2α phosphorylation, thereby increasing PSMB5 protein levels, proteasome activity, and bortezomib resistance in multiple myeloma cells. METTL16 overexpression/knockdown, eIF2α phosphorylation analysis, polysome profiling/translational assay, proteasome activity assay, PI sensitivity assay Oncogene Medium 41826420
2030 PSMB5 overexpression in neurons slows age-related decline in spatial learning/memory and neuromuscular function in mice, establishing that neuronal PSMB5-dependent proteasome activity is required for maintenance of cognitive function during aging. Transgenic PSMB5 neuron-specific overexpression in mice, spatial learning/memory behavioral assays, neuromuscular assessments, proteasome activity assays in aged brain bioRxivpreprint Low bio_10.1101_2024.10.17.618893

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 387 18565852
2010 Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 151 20555361
2012 Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. The Journal of pharmacology and experimental therapeutics 85 22235146
2008 Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Experimental hematology 67 18562081
2014 Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy. The Journal of biological chemistry 64 24627483
2009 Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Experimental hematology 63 19426847
2017 PSMB5 plays a dual role in cancer development and immunosuppression. American journal of cancer research 55 29218236
2006 Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. Biochemical and biophysical research communications 48 16723119
2020 Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 40 32866906
2021 EGCG inhibits pressure overload-induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6-dependent signalling pathways. Acta physiologica (Oxford, England) 35 33315278
2019 Ilexgenin A inhibits mitochondrial fission and promote Drp1 degradation by Nrf2-induced PSMB5 in endothelial cells. Drug development research 32 30762899
2018 PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer. The International journal of biological markers 30 28623645
2019 Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5. FEBS letters 28 31562641
2014 Ameliorating replicative senescence of human bone marrow stromal cells by PSMB5 overexpression. Biochemical and biophysical research communications 22 24393841
2010 G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis 21 20478922
2020 The role of PSMB5 in sodium arsenite-induced oxidative stress in L-02 cells. Cell stress & chaperones 16 32301004
2022 Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndrome. Proceedings of the National Academy of Sciences of the United States of America 13 35617426
2017 20-HETE regulated PSMB5 expression via TGF-β/Smad signaling pathway. Prostaglandins & other lipid mediators 13 28807746
1997 Structural analysis and chromosomal localization of the mouse Psmb5 gene coding for the constitutively expressed beta-type proteasome subunit. Immunogenetics 12 9382924
2024 Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 9 39037181
2002 Sequencing of amphioxus PSMB5/8 gene and phylogenetic position of agnathan sequences. Gene 9 11814690
2022 ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5. JCI insight 8 36040812
2022 PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis. Disease markers 8 36061354
2021 Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells. Oxidative medicine and cellular longevity 8 34394840
2005 Natural selection during functional divergence to LMP7 and proteasome subunit X (PSMB5) following gene duplication. Journal of molecular evolution 8 15785850
2025 The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation. Nature communications 7 39952963
2025 Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression. Nature communications 6 39929834
2023 Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation. Acta biochimica et biophysica Sinica 6 38009004
2012 Polyclonal antibodies against human proteasome subunits PSMA3, PSMA5, and PSMB5. Hybridoma (2005) 5 22894781
2025 Targeting the proteasome subunit PSMB5 by RNA interference induces proteasome dysfunction and mortality in the Colorado potato beetle (Leptinotarsa decemlineata). Scientific reports 4 41272274
2024 DNA Methylation Profiles of PSMA6, PSMB5, KEAP1, and HIF1A Genes in Patients with Type 1 Diabetes and Diabetic Retinopathy. Biomedicines 3 38927561
2017 [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 3 29365400
2025 HBV Infection Drives PSMB5-Dependent Proteasomal Activation in Humanized Mice and HBV-Associated HCC. Viruses 1 41305476
2024 MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5. Molecular biology reports 1 38252234
2010 [Expression of proteasome subunits PSMB5 and PSMB9 mRNA in hippocampal neurons in experimental diabetes mellitus: link with apoptosis and necrosis]. Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 1 20968039
2026 METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation. Oncogene 0 41826420
2026 VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma. Scientific reports 0 41839959
2025 Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery. Frontiers in immunology 0 41409300
2021 1,4-dihydropyridine derivatives increase mRNA expression of Psma3, Psmb5, and Psmc6 in rats. Arhiv za higijenu rada i toksikologiju 0 34187104

Missed literature

Know a paper Affinage missed for PSMB5? Flag it for the maintainers and the community.

No submissions yet.